Archive for the ‘Blood / Hematology’ Category

Romiplostim Data Show Potential Long-Term Efficacy And Safety In Adults With Chronic ITP

Tuesday, June 17th, 2008

Amgen Inc. (NASDAQ: AMGN) announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show ...

Health Economic Analysis Reports That Revlimid Is A Cost Effective Treatment For Multiple Myeloma

Monday, June 16th, 2008

Celgene International Sarl (Nasdaq:CELG) announced that data presented at the 13th Congress of the European Hematology Association (EHA) in Copenhagen, Denmark found that patients previously treated for multiple myeloma receiving REVLIMID (lenalidomide) in combination with dexamethasone experienced a significant survival gain regardless of the number of prior therapies they had ...

Risk Of Contamination From Unsafe Blood - China And United Arab Emirates Make Rapid Progress

Monday, June 16th, 2008

China and the United Arab Emirates (UAE) have made impressive strides in tackling the risk of contamination from unsafe blood by reaching close to 100% voluntary blood donation , said the World Health Organization today . Their efforts to increase their safe blood base will be promoted as models for ...

Many Happy Returns For National Blood Donor Week, Canada

Saturday, June 14th, 2008

Today marks the beginning of the first National Blood Donor Week recognized by the Government of Canada. The week, culminating June 14 on World Blood Donor Day, is an opportunity to thank volunteer donors for their selfless life-saving act, call upon others to join them, and remind Canadians of ...

The Strategy And Business Of Engineered Blood Substitutes

Thursday, June 12th, 2008

Transfusions of whole blood and blood components represent one of the most widely used life-saving procedures in the healthcare sector. But the complexities of human blood including the risks of transmitting blood borne diseases and the uncertainty of adequate factor-matched supplies have long been the Achilles heel of a system ...

Boehringer Ingelheim Announces First Positive Health Technology Assessments For Novel Oral Anticoagulant Pradaxa(R) (dabigatran Etexilate)

Wednesday, June 11th, 2008

The Scottish Medicines Consortium (SMC) has accepted Pradaxa® (dabigatran etexilate) for routine use within the National Health Service (NHS) of Scotland for its currently licensed indication: the prevention of venous thromboembolic events in adults who have undergone total hip or knee replacement surgery. The European Commission granted marketing authorisation ...

Potential For Sensitive Blood Test To Identify Type 1 Diabetes

Tuesday, June 10th, 2008

Knowing who has, or will develop Type-1 diabetes is of immense clinical significance, even as the number of cases of the much more common Type-2 diabetes skyrocket. Because of technology developed at Antigen Express, the wholly-owned subsidiary of NASDAQ-listed oral insulin delivery company Generex Biotechnology, Antigen Express collaborators are now ...

Global Bleeding Disorders Community Gathers In Istanbul

Tuesday, June 10th, 2008

The XXVIII World Congress on hemophilia and related bleeding disorders opened in Istanbul, attracting over 4,200 leading healthcare professionals and delegates from over 115 countries. It is the largest WFH congress in terms of both number of delegates and number of countries represented. New research in diagnosis, management and treatment ...

World Federation Of Hemophilia Closes The Gap In Hemophilia Care

Tuesday, June 10th, 2008

The World Federation of Hemophilia (WFH) has played a key role in bringing about great improvements in the diagnosis and treatment of all people with bleeding disorders, according to data presented by WFH president Mark Skinner at the organization's XXVIII annual meeting in Istanbul, Turkey, this week. "We can demonstrate ...

European Medicines Agency Recommends Measures To Manage Contamination Ofheparin-Containing Medicines

Tuesday, June 10th, 2008

The European Medicines Agency has reviewed the risks associated with the use of heparin medicinal products contaminated with oversulphated chondroitin sulphate (OSCS). Heparins are used to prevent and treat blood clots. They are used widely in patients who could have, or have had a heart attack, in patients who have ...

Research Shows VASER Ultrasound Assisted Lipoplasty Patients Experience Significantly Lower Blood Loss

Saturday, June 7th, 2008

Findings from a comparative analysis study of blood loss during lipoplasty procedures shows VASER ultrasound-assisted lipoplasty causes significantly less blood loss when compared to traditional tumescent lipoplasty. Results of the study were presented at the annual meeting of the American Society for Aesthetic Plastic Surgery held the first week of ...

US Department Of Defense Recommends Soldiers Carry WoundStat™ For Life-Threatening Bleeding

Saturday, June 7th, 2008

TraumaCure Inc. announced that the DOD Joint Committee on Tactical Combat Casualty Care (CoTCCC) has recommended that U.S. soldiers from all services carry the company's hemostatic agent, WoundStat™. The CoTCCC based its recommendations upon the results of extensive studies conducted by both the Army's Institute for Surgical Research (ISR) and ...

ZymoGenetics Announces FDA Approval Of RECOTHROMTM 20,000-IU Vial Size And Co-Packaging With Spray Kit

Monday, June 2nd, 2008

ZymoGenetics, Inc. (NASDAQ:ZGEN) announced that the United States Food and Drug Administration (FDA) has approved a Prior Approval Supplement application for a 20,000 international unit (IU) vial of RECOTHROMTM Thrombin, topical (Recombinant) and also approved co-packaging of the 20,000-IU vial with the ZymoGenetics Spray Applicator Kit. "RECOTHROM, the first and ...

NIMS’ Acceleration Platform Technology Effective In Severe Experimental Hemorrhagic Shock

Monday, June 2nd, 2008

Marvin A Sackner, M.D., Chief Executive Officer and Chairman, Board of Directors, Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU) announced that Dr. Jose A Adams, Dr. Uryash and their group at Mount Sinai Medical Center of Greater Miami presented two papers at the 9th Scientific Congress of the European Resuscitation Council ...

Sanofi-aventis Withdraws Its Marketing Authorisation Application ForAquilda (satavaptan), Europe

Friday, May 30th, 2008

The European Medicines Agency (EMEA) has been formally notified by Sanofi-Aventis of its decision to withdraw the application for a centralised marketing authorisation for the medicine Aquilda (satavaptan) 5 and 25 mg film-coated tablets. Aquilda was intended to be used for the treatment of euvolaemic and hypervolaemic dilutional hyponatraemia, a ...